171 related articles for article (PubMed ID: 23780657)
21. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma.
Eilber FC; Brennan MF; Eilber FR; Eckardt JJ; Grobmyer SR; Riedel E; Forscher C; Maki RG; Singer S
Ann Surg; 2007 Jul; 246(1):105-13. PubMed ID: 17592298
[TBL] [Abstract][Full Text] [Related]
22. [Combination effect of pirarubicin, ifosfamide, and vincristine sulfate in the treatment of advanced synovial sarcoma--report of a case].
Shinozaki T; Matsushita M; Kusawake H; Watanabe H; Arita S; Chigira M; Udagawa E
Gan To Kagaku Ryoho; 1995 Sep; 22(10):1389-91. PubMed ID: 7668875
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
D'Ambrosio L; Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz D; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; Gronchi A;
Cancer; 2020 Jun; 126(11):2637-2647. PubMed ID: 32129883
[TBL] [Abstract][Full Text] [Related]
25. A case of renal synovial sarcoma treated with adjuvant ifosfamide and doxorubicin.
Ozkan EE; Mertsoylu H; Ozardali HI
Intern Med; 2011; 50(15):1575-80. PubMed ID: 21804284
[TBL] [Abstract][Full Text] [Related]
26. Synovial sarcoma in children: surgical lessons from a single institution and review of the literature.
Andrassy RJ; Okcu MF; Despa S; Raney RB
J Am Coll Surg; 2001 Mar; 192(3):305-13. PubMed ID: 11245372
[TBL] [Abstract][Full Text] [Related]
27. Ifosfamide and actinomycin-D, added in the induction phase to vincristine, cyclophosphamide and doxorubicin, improve histologic response and prognosis in patients with non metastatic Ewing's sarcoma of the extremity.
Ferrari S; Mercuri M; Rosito P; Mancini A; Barbieri E; Longhi A; Rimondini S; Cesari M; Ruggieri P; Di Liddo M; Bacci G
J Chemother; 1998 Dec; 10(6):484-91. PubMed ID: 9876058
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
[TBL] [Abstract][Full Text] [Related]
29. Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma.
Ferrari A; De Salvo GL; Dall'Igna P; Meazza C; De Leonardis F; Manzitti C; De Ioris MA; Casanova M; Carli M; Bisogno G
Eur J Cancer; 2012 Dec; 48(18):3448-55. PubMed ID: 22835783
[TBL] [Abstract][Full Text] [Related]
30. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
31. Salvage treatment experience in advanced synovial sarcoma: a multicenter retrospective analysis of the Anatolian society of medical oncology.
Yetisyigit T; Arpaci E; Seber ES; Kucukoner M; Kos FT; Sonmez OU; Alici S; Akman T; Aktas B; Yildiz R; Gunaydin Y; Inanc M; Demirci U; Alkis N; Gumus M
Asian Pac J Cancer Prev; 2013; 14(9):5185-8. PubMed ID: 24175798
[TBL] [Abstract][Full Text] [Related]
32. Treatment and outcomes for synovial sarcoma patients in Western Australia: the role of neoadjuvant chemoradiotherapy.
Khan Y; Carey-Smith R; Taylor M; Woodhouse J; Jacques A; Wood D; Long A
Cancer Rep (Hoboken); 2020 Dec; 3(6):e1268. PubMed ID: 32881345
[TBL] [Abstract][Full Text] [Related]
33. Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy.
Penel N; Italiano A; Isambert N; Bompas E; Bousquet G; Duffaud F;
Ann Oncol; 2010 Jun; 21(6):1361-1365. PubMed ID: 19880438
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States.
Pollack SM; Somaiah N; Araujo DM; Druta M; Van Tine BA; Burgess MA; Chawla SP; Seetharam M; Okuno SH; Bohac C; Chen M; Yurasov S; Attia S
Cancer Med; 2020 Jul; 9(13):4593-4602. PubMed ID: 32374488
[TBL] [Abstract][Full Text] [Related]
35. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
36. Results of the EICESS-92 Study: two randomized trials of Ewing's sarcoma treatment--cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients.
Paulussen M; Craft AW; Lewis I; Hackshaw A; Douglas C; Dunst J; Schuck A; Winkelmann W; Köhler G; Poremba C; Zoubek A; Ladenstein R; van den Berg H; Hunold A; Cassoni A; Spooner D; Grimer R; Whelan J; McTiernan A; Jürgens H;
J Clin Oncol; 2008 Sep; 26(27):4385-93. PubMed ID: 18802150
[TBL] [Abstract][Full Text] [Related]
37. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
38. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
Verma S; Younus J; Stys-Norman D; Haynes AE; Blackstein M;
Cancer Treat Rev; 2008 Jun; 34(4):339-47. PubMed ID: 18313854
[TBL] [Abstract][Full Text] [Related]
39. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
Harris MB; Gieser P; Goorin AM; Ayala A; Shochat SJ; Ferguson WS; Holbrook T; Link MP
J Clin Oncol; 1998 Nov; 16(11):3641-8. PubMed ID: 9817286
[TBL] [Abstract][Full Text] [Related]
40. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas.
Patel SR; Vadhan-Raj S; Burgess MA; Plager C; Papadopolous N; Jenkins J; Benjamin RS
Am J Clin Oncol; 1998 Jun; 21(3):317-21. PubMed ID: 9626808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
